A CAR enhancer increases the activity and persistence of CAR T cells
Taha Rakhshandehroo(Dana-Farber Cancer Institute), Shreya R. Mantri(Dana-Farber Cancer Institute), Seyed Heydar Moravej(Dana-Farber Cancer Institute), Benjamin B. V. Louis(Dana-Farber Cancer Institute), Ali Salehi Farid(Dana-Farber Cancer Institute), Leila Munaretto(Dana-Farber Cancer Institute), Kathryn Regan(Boston University), Radia M. M. Khan(Dana-Farber Cancer Institute), A Wolff(Dana-Farber Cancer Institute), Zoe Farkash(Dana-Farber Cancer Institute), Min Cong(Dana-Farber Cancer Institute), Adrien Kuhnast(Dana-Farber Cancer Institute), Ali Nili(Dana-Farber Cancer Institute), Uk‐Jae Lee(Dana-Farber Cancer Institute), Harris H. Allen(Dana-Farber Cancer Institute), Léa Berland(Dana-Farber Cancer Institute), Ester Simkova(Dana-Farber Cancer Institute), Safak Uslu(Dana-Farber Cancer Institute), Soheil Tavakolpour(Dana-Farber Cancer Institute), Jennifer Rowley(Boston University), Elisabeth Codet(Dana-Farber Cancer Institute), Haneyeh Shahbazian(Dana-Farber Cancer Institute), Jessika Baral(Harvard University), Jason W. Pyrdol(Dana-Farber Cancer Institute), Caron A. Jacobson(Harvard University), Omar Nadeem(Harvard University), Hadi T. Nia(Boston University), Kai W. Wucherpfennig(Harvard University), Mohammad Rashidian(Brigham and Women's Hospital)
Cited by 38Open Access
Abstract
Related Papers
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al.|Journal of Clinical Investigation|2016|2.1k
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas et al.|Journal of Clinical Investigation|2016|1.1k